Bond David J, Silveira Leonardo E, Torres Ivan J, Lam Raymond W, Yatham Lakshmi N
Department of Psychiatry and Behavioral Sciences, University of Minnesota Medical School, Minneapolis, MN, USA.
Mood Disorders Centre, University of British Columbia, Vancouver, BC, Canada.
Psychol Med. 2021 Mar 12:1-9. doi: 10.1017/S0033291721000544.
We previously reported that bipolar disorder (BD) patients with clinically significant weight gain (CSWG; ⩾7% of baseline weight) in the 12 months after their first manic episode experienced greater limbic brain volume loss than patients without CSWG. It is unknown whether CSWG is also a risk factor for progressive neurochemical abnormalities.
We investigated whether 12-month CSWG predicted greater 12-month decreases in hippocampal N-acetylaspartate (NAA) and greater increases in glutamate + glutamine (Glx) following a first manic episode. In BD patients (n = 58) and healthy comparator subjects (HS; n = 34), we measured baseline and 12-month hippocampal NAA and Glx using bilateral 3-Tesla single-voxel proton magnetic resonance spectroscopy. We used general linear models for repeated measures to investigate whether CSWG predicted neurochemical changes.
Thirty-three percent of patients and 18% of HS experienced CSWG. After correcting for multiple comparisons, CSWG in patients predicted a greater decrease in left hippocampal NAA (effect size = -0.52, p = 0.005). CSWG also predicted a greater decrease in left hippocampal NAA in HS with a similar effect size (-0.53). A model including patients and HS found an effect of CSWG on Δleft NAA (p = 0.007), but no diagnosis effect and no diagnosis × CSWG interaction, confirming that CSWG had similar effects in patients and HS.
CSWG is a risk factor for decreasing hippocampal NAA in BD patients and HS. These results suggest that the well-known finding of reduced NAA in BD may result from higher body mass index in patients rather than BD diagnosis.
我们之前报道过,双相情感障碍(BD)患者在首次躁狂发作后的12个月内出现具有临床意义的体重增加(CSWG;≥基线体重的7%),其边缘脑区体积损失比未出现CSWG的患者更大。目前尚不清楚CSWG是否也是进行性神经化学异常的危险因素。
我们调查了首次躁狂发作后12个月的CSWG是否预示着海马体N-乙酰天门冬氨酸(NAA)有更大幅度的下降以及谷氨酸+谷氨酰胺(Glx)有更大幅度的增加。在BD患者(n = 58)和健康对照者(HS;n = 34)中,我们使用双侧3特斯拉单体素质子磁共振波谱测量基线和12个月时的海马体NAA和Glx。我们使用重复测量的一般线性模型来研究CSWG是否能预测神经化学变化。
33%的患者和18%的HS出现了CSWG。在进行多重比较校正后,患者中的CSWG预示着左海马体NAA有更大幅度的下降(效应量 = -0.52,p = 0.005)。CSWG在HS中也预示着左海马体NAA有类似效应量(-0.53)的更大幅度下降。一个包含患者和HS的模型发现CSWG对左NAA的变化量有影响(p = 0.007),但没有诊断效应,也没有诊断×CSWG相互作用,证实了CSWG在患者和HS中有类似的效应。
CSWG是BD患者和HS中海马体NAA下降的危险因素。这些结果表明,BD患者中NAA降低这一众所周知的发现可能是由于患者较高的体重指数,而非BD诊断所致。